CGTN: Tibetan Religious Leader Extends Wishes for Spring Festival, Tibetan New Year
12.2.2021 16:50:00 EET | Business Wire | Press release
The Tibetan New Year falls on the same day as the Spring Festival this year. As a long, bitter winter starts petering down, colorful spring sneaks in.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210212005297/en/
Bainqen Erdini Qoigyijabu, the 11th Panchen Lama, on Friday expressed best wishes to all Tibetans at home and abroad for both the Spring Festival and the Tibetan Year of the Iron Ox through China Media Group (CMG) and China Tibet Online.
Looking back at the past year, he expressed his affirmation that China has overcome difficulties in the face of the pandemic. "The whole country united together, and all people worked with one heart, achieving outstanding results in preventing and controlling the COVID-19 pandemic, which draws much worldwide attention," he said.
"From the pandemic, we have further understood how precious life is. As I see it, health, peace and happiness are the most precious fortune in human life. From the pandemic, we have also further understood that all human beings are in a community with a shared future."
He also expressed his understanding of the importance of a community with a shared future for mankind.
Erdini Qoigyijabu spoke of the historic alleviation of poverty in Tibet and of people in the region living and working in peace and contentment, and expressed his sincere gratitude to the country. "I feel very gratified to see the new Tibet today," he said. "A glorious time and a happy homeland is not a gift from nature. We should remain grateful for our country, and for the thousands upon thousands of people willing to sacrifice for us.”
Finally, he offered New Year blessings to the people of the whole country. "Let us jointly wish and pray the world be peaceful, the country be prosperous, the people live in peace, the weather be favorable, and all living things live joyfully! I wish everyone and every family be happy, safe and sound in the New Year and reap a new harvest," he concluded.
The Tibetan New Year, known as Losar, is the most important festival on the Tibetan calendar.
Celebrating Losar, Tibetan New Year, on the plateau
Losar is roughly the same as the Spring Festival of the Han ethnic group.
The Tibetan New Year is calculated based on the Tibetan calendar. It starts on the first day of the first month of the Tibetan calendar and ends on the 15th day. It falls on February 12 this year.
Originally a harvest celebration, the festival gradually shifted to the beginning of a new year, after Princess Wencheng of the Tang Dynasty (618-907) married Songtsen Gampo, the then Tibetan King, and brought to the southwestern Chinese region the culture of the Han people.
For the Tibetans and those who have been exploring the Tibetan New Year on the plateau, Tashi delek, and Happy New Year!
A developing Tibet
Transportation has long been a bottleneck inhibiting Tibet's development, as the region is situated on the Qinghai-Tibet Plateau with complex geographical conditions for road construction and limited technology and funds.
Since late 2012, China has been bolstering its infrastructure investment in Tibet. So far, roads have connected 95 percent of the township-level administrations and 75 percent of the incorporated villages in the region. The road network in Tibet now stretches over 117,000 kilometers, up by 50 percent from the end of 2015.
As for air transportation, Tibet has launched a total of 130 air routes, with 61 cities connected by flights; 5.18 million passenger trips were registered in 2020.
The development of Tibet is well-founded with data.
With the strong support of the central government and the active assistance from the local people, the economy of Tibet has been developing steadily.
In 2018, Tibet registered a GDP growth rate of 10 percent, the highest in China.
According to the released work reports from the local governments in February 2021, Tibet led the 2020 growth rate among the country's 31 provincial-level regions, at 7.8 percent, followed by southwestern provinces of Guizhou and Yunnan, at 4.5 and 4 percent, respectively.
In 2021, Tibet's GDP growth target stands at over 9 percent, while the pace is set around 8 percent for Guizhou and Yunnan provinces.
Original article: here.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210212005297/en/
Contact information
Media:
Jiang Simin
jiang.simin@cgtn.com
+86 18826553286
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
